
NOSOPHARM AND GNA NOW ANNOUNCE POSITIVE RESULTS FOR THE LATE PRECLINICAL DEVELOPMENT OF THE FIRST-IN-CLASS ANTIBIOTIC NOSO-502
An important milestone has been reached for the GNA NOW Consortium with the completion of the GLP toxicology studies for the NOSO-502 program. The results allow for the further development of the program to Phase 1 Utrecht, the Netherlands, and Lyon, France, 8 June 2022 Nosopharm, a biotechnology company specialized in exploring unconventional sources of antibiotics to discover new drugs to fight antimicrobial resistance, today announces the completion and positive results of toxicology studies for NOSO-502, a first-in-class antibiotic for the treatment of multidrug-resistant hospital-acquired infections. NOSO-502 is being developed by Nosopharm in partnership with GNA NOW, a European Consortium funded by the Innovative Medicines Initiative 2 (IMI2). NOSO-502 is the first clinical candidate in the new class of antibiotics called Odilorhabdins. It was discovered by Nosopharm from a Xenorhabdus bacteria. NOSO-502 is intended for the treatment of the main hospital-acquired infections caused by the multidrug-resistant Enterobacterales: Escherichia coli, Klebsiella